Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
life sciences
national blog main
national top stories
roche
3
×
avapritinib
blueprint medicines
deals
eli lilly
europe blog main
europe top stories
genentech
medullary thyroid cancer
non-small cell lung cancer
pralsetinib
san francisco blog main
san francisco top stories
selpercatinib
thyroid cancer
biopharma
cancer
cancer drugs
capmatinib
clinical trials
cstone pharmaceuticals
duchenne
european medicines agency
fda
fisogatinib
flatiron health
gastrointestinal stromal tumors
hepatocellular carcinoma
indiana blog main
indiana top stories
investing
jeff albers
licensing
What
approval
3
×
fda
blueprint
cancer
drug
medicines
ret
roche
therapy
address
approves
betting
billion
biopharma
candidate
carries
certain
currently
deal
designed
duchenne
gene
genetic
historic
latest
marketing
medicine
muscle
pact
pass
puts
recently
regulatory
review
rna
sarepta
second
signature
signatures
swiss
Language
unset
Current search:
roche
×
approval
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal